Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
88% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. MNOV: No Debt )
MNOV' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: No Debt

Interest Coverage No Debt
MNOV's Interest Coverage is ranked higher than
63% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNOV: No Debt )
MNOV' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -5.81
M-Score: 141.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -56.88
MNOV's Operating margin (%) is ranked higher than
75% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. MNOV: -56.88 )
MNOV' s 10-Year Operating margin (%) Range
Min: -15787.12   Max: -66.98
Current: -56.88

-15787.12
-66.98
Net-margin (%) -56.68
MNOV's Net-margin (%) is ranked higher than
75% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. MNOV: -56.68 )
MNOV' s 10-Year Net-margin (%) Range
Min: -13518.94   Max: -67.12
Current: -56.68

-13518.94
-67.12
ROE (%) -14.02
MNOV's ROE (%) is ranked higher than
80% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. MNOV: -14.02 )
MNOV' s 10-Year ROE (%) Range
Min: -788.84   Max: -19.99
Current: -14.02

-788.84
-19.99
ROA (%) -11.78
MNOV's ROA (%) is ranked higher than
80% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. MNOV: -11.78 )
MNOV' s 10-Year ROA (%) Range
Min: -172.07   Max: -16.41
Current: -11.78

-172.07
-16.41
ROC (Joel Greenblatt) (%) -214.41
MNOV's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. MNOV: -214.41 )
MNOV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39131.25   Max: -108.93
Current: -214.41

-39131.25
-108.93
EBITDA Growth (3Y)(%) -49.40
MNOV's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. MNOV: -49.40 )
MNOV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.3   Max: 188.9
Current: -49.4

-83.3
188.9
EPS Growth (3Y)(%) -51.20
MNOV's EPS Growth (3Y)(%) is ranked higher than
55% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MNOV: -51.20 )
MNOV' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.2   Max: 254
Current: -51.2

-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MNOV Guru Trades in

MNOV Guru Trades in

MNOV Guru Trades in

Q3 2014

MNOV Guru Trades in Q3 2014

Jim Simons 49,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.27
MNOV's P/B is ranked higher than
83% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. MNOV: 3.27 )
MNOV' s 10-Year P/B Range
Min: 0.18   Max: 4.68
Current: 3.27

0.18
4.68
P/S 11.52
MNOV's P/S is ranked higher than
80% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. MNOV: 11.52 )
MNOV' s 10-Year P/S Range
Min: 6.48   Max: 1210
Current: 11.52

6.48
1210
PFCF 155.50
MNOV's PFCF is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNOV: 155.50 )
MNOV' s 10-Year PFCF Range
Min: 116   Max: 208
Current: 155.5

116
208
Current Ratio 11.13
MNOV's Current Ratio is ranked higher than
88% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MNOV: 11.13 )
MNOV' s 10-Year Current Ratio Range
Min: 1.31   Max: 49.29
Current: 11.13

1.31
49.29
Quick Ratio 11.13
MNOV's Quick Ratio is ranked higher than
89% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. MNOV: 11.13 )
MNOV' s 10-Year Quick Ratio Range
Min: 1.31   Max: 49.29
Current: 11.13

1.31
49.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.37
MNOV's Price/Net Cash is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. MNOV: 10.37 )
MNOV' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 30.33
Current: 10.37

0.71
30.33
Price/Net Current Asset Value 10.37
MNOV's Price/Net Current Asset Value is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. MNOV: 10.37 )
MNOV' s 10-Year Price/Net Current Asset Value Range
Min: 0.71   Max: 30.33
Current: 10.37

0.71
30.33
Price/Tangible Book 8.64
MNOV's Price/Tangible Book is ranked higher than
73% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. MNOV: 8.64 )
MNOV' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 54.67
Current: 8.64

0.4
54.67
Price/Median PS Value 0.04
MNOV's Price/Median PS Value is ranked higher than
99% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. MNOV: 0.04 )
MNOV' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 4.06
Current: 0.04

0.03
4.06
Earnings Yield (Greenblatt) -5.40
MNOV's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. MNOV: -5.40 )
MNOV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 60.9   Max: 8448.3
Current: -5.4

60.9
8448.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Traded in other countries:4875.Japan, RMN.Germany,
MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core programs includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.
» More Articles for MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Dec 09 2014
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment... Dec 09 2014
MediciNova (MNOV) Looks Good: Stock Soars 19.3% Dec 02 2014
MEDICINOVA INC Financials Nov 21 2014
10-Q for MediciNova, Inc. Nov 15 2014
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Nov 14 2014
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical... Oct 23 2014
U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical... Oct 23 2014
MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic... Oct 22 2014
MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic... Oct 22 2014
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 17 2014
MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001... Oct 08 2014
MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual... Oct 06 2014
Overview of MediciNova's Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at The 13th... Sep 29 2014
MediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Sep 23 2014
MediciNova Rises on FDA's Nod on MN-166 Study Initiation Aug 28 2014
MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 19 2014
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Aug 14 2014
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report Aug 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK